Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.
-----------
US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.
Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.
The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.
Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.
But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."
Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway.
------------ Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts
The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event."
Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure.
They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process.
Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac.
Latest news on Sinovac in Brazil =========================
“It was a death, but from an external cause, with no relation to the vaccine. I repeat, a serious adverse event that is unrelated to the vaccine. This information has been available to Anvisa,” said Dimas Covas, president of the Butantan Institute.
Police are investigating the death as a suicide, according to the São Paulo public health secretary.
Sinopharm on Friday released details of a case of Huawei's Mexico branch, where 81 out of 99 staff were inoculated with the vaccine. Ten unvaccinated employees contracted the virus in an outbreak in this office.
The Mexico case alone showed a 100 percent efficacy, which has contributed to the evaluation of Sinopharm's inactivated vaccine candidate, Tao Lina, a Shanghai-based vaccine expert, told the Global Times on Tuesday.
Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.
SUICIDE halts Brazil trial of Chinese vaccine attacked by Bolsonaro
The trial’s organizers criticized Anvisa’s decision, saying they had not been notified in advance and that there was no reason to stop the trial.
Although a trial volunteer had died, it had nothing to do with the vaccine, Jean Gorinchteyn, Health Secretary for the state of Sao Paulo told a news conference on Tuesday.
“We had an external event that led to the regulator being notified,” Gorinchteyn said. “This vaccine is safe.”
Dimas Covas, the head of Sao Paulo’s medical research institute Butantan, which is conducting the Sinovac trial, said the vaccine had shown no serious adverse effects. Speaking at the same news conference, he said he hoped the trial would be resumed later on Tuesday or Wednesday.
Anvisa said the initial information it received from Butantan had not specified that the death was a SUICIDE.
Administered to more than 100,000 people in China, vaccines developed by public entity SINOPHARM against Covid-19 are in their final stages of testing. Morocco, which is participating to the process, will launch an expanded vaccination campaign in the coming weeks.
Dr Yahyane stressed that these trials «have not been completed yet», but that «they have reached the final phase». They are also monitored by «a scientific and technical committee, made up of independent researchers, national and international authorities recognized on a larger scale by their scientific publications and appointed by the Ministry of Health».
Abdelhakim Yahyane told Yabiladi that on Thursday, November 5, the second presentation of these tests allowed the committee to analyze the progress of this process, which is «positive» and whose results will be announced soon. «We have already noted that there have been no major adverse effects and those which have been observed are very minimal, quite normal, as is the case for all other vaccines», he declared.
The third phase of the trials allows us to better understand the side effects of the vaccine, which would not have been identified during the first two stages of the tests. In September, the Chinese government and Sinopharm did not report any adverse effects. So far, none of the people who have been vaccinated have contracted Covid-19.
«We are impatiently awaiting the end of this process, which could probably HAPPEN BY NEXT WEEK, to then receive the results from the Chinese laboratory. The protocol indeed requires that the latter to finalize the analyses and define a protocol, with scientific methods, before they are approved by Morocco», added Dr. Abdelhakim Yahyane.
u bot 5 lot, and tp@0.93, and u feel proud and laughing at others? how about those holding since 0.4 with big lots and when they tp above 1, they laughing at you?
There r still Mexico and Indonesia, why so panic. These halts are just delays. Lol. Just the matter of time, value investment lol. Look ahead. Manipulators are manipulators.
Regardless of what vaccine available, we need a cold environment for the transportation of vaccine. Kelington Group Berhad has been selling dry ice which is definitely a growing prospect for this company. - We all know that for the current covid-19 vaccine developed from Pfizer, its storing temperature needs to be around -70C, even other vaccines developed by other companies need to be stored around -40C also. This is definitely boost the future prospect of this company. - The company has all time high orderbook that is valued at RM386m due to demand that coming from industry such as semiconductor - Their liquid CO2 plant is starting to show profit
At current price, KGB still has much space to grow in terms, not to mention future profitability
if can stay above 0.8, most probably will go up again if cant, then have to see if 0.75 level can hold definitely have to undergo some correction before moving upward again
Brazil on Wednesday RESUMED the trials of a Chinese COVID-19 vaccine after halting them on Monday over a mysterious death. The reported "severe adverse event" was later said to be not related to the vaccine but likely a suicide.
Brazil's National Health Surveillance Agency (Anvisa) announced on Wednesday morning local time to resume the trial of a vaccine candidate developed by Chinese firm Sinovac Biotech (Sinovac) .
It is unclear how the case triggered a sudden suspension of the trial but analysts suspect political involvement.
The Butantan Institute, a Sao Paulo-based sponsor of the trial, told the Global Times that it had sent notice of the volunteer's death to Anvisa on November 6. "In conclusion, it was stated that the death was not related to the test vaccine," said the statement sent by the Butantan Institute.
What: CanSino has also developed a viral vector vaccine, using a weakened version of the adenovirus as a vehicle for introducing the SARS-CoV-2 spike protein to the body. Preliminary results from phase two trials, published in The Lancet, have shown that the vaccine produces “significant immune responses in the majority of recipients after a single immunisation.” There were no serious adverse reactions documented.
Status: Though the company was still technically in phase two of its trial, on June 25, CanSino became the first company to receive limited approval to use its vaccine in people. The Chinese government has approved the vaccine for military use only, for a period of one year. On August 15, Russian biopharmaceutical company Petrovax announced it had launched the first phase three clinical trial of Ad5-nCoV.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
monkey_business
90 posts
Posted by monkey_business > 2020-11-10 19:05 | Report Abuse
Daijiao selling....LOL